Latest News about DSNKY
Recent news which mentions DSNKY
   AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
   
  
  
  March 06, 2023
  From Benzinga
 
   Is Gilead Sciences a Good Stock to Buy Now?
   
  
  
  February 06, 2023
  From Motley Fool
 From Benzinga
 
   AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
   
  
  
  December 19, 2022
  From Benzinga
 
   AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
   
  
  
  December 09, 2022
  From Benzinga
 
   European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
   
  
  
  November 14, 2022
  From Benzinga
 
   With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
   
  
  
  September 21, 2022
  From Benzinga
 
   Why MacroGenics Stock Sank Today
   
  
  
  September 12, 2022
  From Motley Fool
 
   This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
   
  
  
  September 12, 2022
  From Benzinga
 
   3 Top Stocks to Invest In Right Now
   
  
  
  August 16, 2022
  From InvestorPlace
 
   Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
   
  
  
  August 15, 2022
  From Benzinga
 
   AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
   
  
  
  August 15, 2022
  From Benzinga
 
   Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
   
  
  
  August 12, 2022
  From Benzinga
 
   AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
   
  
  
  August 09, 2022
  From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 
   EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
   
  
  
  June 27, 2022
  From Benzinga
 From Motley Fool
 
   AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%
   
  
  
  June 06, 2022
  From Benzinga
 
   Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer
   
  
  
  April 27, 2022
  From Benzinga
 From Benzinga
 
   Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer
   
  
  
  April 19, 2022
  From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 
   Here's Why Everyone's Talking About AstraZeneca Right Now
   
  
  
  September 21, 2021
  From Motley Fool
 
   AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
   
  
  
  September 20, 2021
  From Benzinga
 
   AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer
   
  
  
  September 17, 2021
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.